£1.8M
The oversubscribed round was led by Cambridge Enterprise and will fund the company's transition into drug development.
P
PharmEnable
PharmEnable designs complex small molecule drugs using advanced medicinal chemistry and artificial intelligence.
£1.8MTotal raised
PharmEnable is a Cambridge-based drug discovery company that combines advanced medicinal chemistry and artificial intelligence to design complex, specific small molecule drug candidates. The firm focuses on developing new treatments for challenging biological targets in areas such as cancer and neurodegeneration.
Categories
Founders
HS
Hannah Sore
CEO